Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMBER trial of ctDNA ESR1-guided endocrine switching with abemaciclib in HR-positive/HER2-negative advanced breast cancer
jRCTs051220133Phase 2Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of abemaciclib, fulvestrant, letrozole and anastrozole in breast cancer (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: 2-year progression-free survival rate from secondary enrollment. Started Dec 2022; status: recruiting.
02
Drugs
abemaciclibfulvestrantletrozoleanastrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCTs051220133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051220133.